Chengdu Sibeibo divulges new PARP-14 inhibitors

AI Briefing

• – Chengdu Sibeibo develops new PARP-14 inhibitors for cancer, asthma, atopic dermatitis and infectious pneumonia treatment.
• – The new inhibitors show potential therapeutic effects in various diseases.
• – Details of the new compounds and their efficacy are expected to be published in a scientific journal.